<DOC>
	<DOCNO>NCT00814983</DOCNO>
	<brief_summary>The primary objective measure safety efficacy allogeneic stem cell transplantation use peripheral blood stem cell graft deplete CD45RA+ Naive T-cells . The secondary objective measure pace immune recovery .</brief_summary>
	<brief_title>Myeloablative Allogeneic Stem Cell Transplantation Using Naive T-Cell Depleted Peripheral Blood Stem Cell Graft</brief_title>
	<detailed_description>A cohort patient ( Cohort 1 ) enrol receive currently accept standard approach myeloablative allogeneic stem cell transplantation . With exception volume and/or plasma depletion ( case donor/recipient ABO incompatibility ) , peripheral blood stem cell graft unmodified . The primary purpose Cohort 1 prospectively collect sample measurement immune recovery relatively homogeneous population patient treat uniform manner . Within limitation age-matching , patient accrue Cohort 1 incorporate large retrospective historical control group purpose comparison Cohort 2 incidence grade II-IV acute Graft versus Host disease . The experimental aspect trial use na√Øve T-cell deplete peripheral blood stem cell graft ( Cohort 2 ) . All aspect stem cell transplantation line standard care . Recruitment trial stratify donor type match sibling match unrelated donor . Patients condition total body irradiation ( 1350cGy ) Cyclophosphamide . The donor stem cell graft come mobilize peripheral blood 6/6 HLA-identical family member 8/8 ( HLA A , B , C , DRB1 ) allele-level match unrelated donor .</detailed_description>
	<criteria>Age 18 65 year . 8/8 7/8 HLAidentical match sibling OR Allele level 8/8 ( HLAA , B , C , DRbeta1 ) match unrelated donor . Patients high risk ALL first complete remission , high risk define presence ( 4 ; 11 ) , ( 9 ; 22 ) ( 1 ; 19 ) patient present extreme hyperleukocytosis ( WBC &gt; 500,000/ml ) partial remission initial induction therapy . Adult patient acute nonlymphocytic Leukemia ( ANLL ) first complete remission highrisk cytogenetics ( monosomy chromosome 5 7 , del ( 5q ) , abn ( 3q26 ) , complex karyotypic abnormality ) failure achieve complete remission standard induction therapy . All patient ALL ANLL second subsequent remission partial remission ( &lt; 5 % blast bone marrow measure flow cytometry ) . All patient CML chronic ( failed interferon and/or Gleevec ) accelerate phase . Patients myelodysplastic syndrome International Prognostic Scoring System ( IPSS ) risk category INT1 great . Myelofibrosis myeloid metaplasia Patients severe aplastic anemia must fail immunosuppressive therapy cyclosporine plus antithymocyte globulin . Patients history CNS disease must treat active CNS disease time protocol treatment . ECOG performance status &lt; 2 Patients must adequate function organ system measure : Creatinine clearance ( Cockcroft Gault equation [ Appendix IV ] ) &gt; 30ml/min . Hepatic transaminase ( ALT/AST ) &lt; 4 x normal , bilirubin &lt; 2.0 mg/dl . Pulmonary function test demonstrate FVC FEV1 &gt; 50 % predict age DLCO &gt; 50 % predict . Ejection fraction &gt; 45 % echocardiogram , radionuclide scan cardiac MRI . Patients must HIV negative . Patients must pregnant . Patients &gt; 5 % blast bone marrow peripheral circulation . Patients rapidly progressive ANLL ALL .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>myeloablative</keyword>
	<keyword>stem cell</keyword>
	<keyword>naive T-cell deplete</keyword>
	<keyword>allogeneic</keyword>
</DOC>